The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A clinical-stage biopharmaceutical company focused on the discovery and development of innovative medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role.
Blackstone has announced the launch of the Blackstone Life Sciences portfolio company Uniquity Bio, a clinical-stage drug developer on immunology and inflammation. 16 May 2024
The US Food and Drug Administration yesterday granted accelerated approval to Breyanzi (lisocabtagene maraleucel; liso-cel), from US pharma major Bristol Myers Squibb, for a new indication. 16 May 2024
US radiopharmaceuticals company Lantheus Holdings has appointed Dr Jeffrey Humphrey as chief medical officer (CMO) and Dr Jean-Claude Provost as chief science officer (CSO), effective May 28, 2024. 16 May 2024
Shares in Merck KGaA rose by around 5% in Wednesday’s trading after the Germany-based company presented its first quarter financial results and latest forecast for 2024. 15 May 2024
May 15, 2024
Texas, USA-based drugmaker Lexicon Pharmaceuticals saw its shares edge up 2.7% to by close of trading yesterday and a further 2% to $1.96 pre-market as its announced new research results on its heart failure drug. 15 May 2024
A US Food and Drug Administration (FDA) panel will consider Lykos Therapeutics’ filing for midomafetamine capsules (MDMA) as a therapy-assisted treatment for post-traumatic stress disorder (PTSD) in early June. 15 May 2024
Japanese drugmaker Eisai has started the rolling submission of a Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for Leqembi (lecanemab-irmb) subcutaneous (SC) autoinjector for weekly maintenance dosing. 15 May 2024
More leading oncology companies have outlined their planned highlights for the upcoming annual meeting of the American Society of Clinical Oncology (ASCO). 15 May 2024
Four-year data from the SELECT trial will significantly bolster Novo Nordisk’s bid to become the GLP-1 company of choice for payers and prescribers. 15 May 2024
Danish CNS specialist Lundbeck today reported first-quarter 2024 financials, showing that revenues grew 7% at constant exchange rates (CER) and 5% in kroner terms to 5,288 million kroner ($766 million). 15 May 2024
Oxford, UK-based Enara Bio today announces the closing of a $32.5 million Series B financing supported by a strong syndicate of new and existing biotech investors. 3 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024